Therefore, as in the Practice Points summarized in Table 1, unless a cluster of clinical features strongly suggestive of a T1D-like form of GDM (young age, low BMI, early insulin therapy, presence of ketones) is present, autoantibody screening may not be needed, and can be postponed to the follow-up of GDM women, when, for example, a persistent impaired glucose regulation is observed and may be indicative of an unremitting altered beta-cell function. The gene discussed is INS; the disease is type 1 diabetes mellitus.